Amyotrophic Lateral Sclerosis (ALS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Amyotrophic Lateral Sclerosis (ALS) Market Outlook

Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Amyotrophic Lateral Sclerosis (ALS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Amyotrophic Lateral Sclerosis (ALS) Overview

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a degenerative disorder of the nervous system that manifests as progressive muscle wasting and weakness. It is both debilitating and fatal, typically occurring later in life. The disease advances swiftly, with a median survival period of three to five years, and only 20% of patients survive five to ten years after symptom onset. Respiratory failure is the most common cause of death in ALS patients. Despite the generally grim prognosis, there is significant variability in survival rates. As many as 10% of individuals with ALS manage to live more than eight years following the emergence of initial symptoms. Genetic risk factors include gene mutations such as SOD1, TARDBP, FUS, C9orf72, TBK1, and NEK1. Most of these risk factors have been uncovered within the past decade.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Amyotrophic Lateral Sclerosis (ALS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034